Tower Research Capital (TRC)’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,096
| Closed | -$6.19K | – | 5989 |
|
|
2024
Q4 | $6.19K | Buy |
3,096
+1,356
| +78% | +$2.75K | ﹤0.01% | 4196 |
|
|
2024
Q3 | $4.33K | Sell |
1,740
-1,465
| -46% | -$4.2K | ﹤0.01% | 4585 |
|
|
2024
Q2 | $11.2K | Buy |
3,205
+3,087
| +2,616% | +$17.9K | ﹤0.01% | 4098 |
|
|
2024
Q1 | $1.31K | Buy |
118
+27
| +30% | +$320 | ﹤0.01% | 5283 |
|
|
2023
Q4 | $1.1K | Sell |
91
-1
| -1% | -$23 | ﹤0.01% | 5435 |
|
|
2023
Q3 | $4.86K | Buy |
92
+17
| +23% | +$1.2K | ﹤0.01% | 4804 |
|
|
2023
Q2 | $6.59K | Sell |
75
-32
| -30% | -$2.64K | ﹤0.01% | 4681 |
|
|
2023
Q1 | $9K | Buy |
+107
| New | +$9.89K | ﹤0.01% | 4564 |
|
|
2022
Q4 | – | Sell |
-19
| Closed | -$14K | – | 6484 |
|
|
2022
Q3 | $14K | Buy |
19
+16
| +533% | +$5.12K | ﹤0.01% | 4232 |
|
|
2022
Q2 | $1K | Sell |
3
-26
| -90% | -$10K | ﹤0.01% | 5884 |
|
|
2022
Q1 | $15K | Buy |
29
+10
| +53% | +$7.47K | ﹤0.01% | 3845 |
|
|
2021
Q4 | $19K | Buy |
19
+4
| +27% | +$5.78K | ﹤0.01% | 3752 |
|
|
2021
Q3 | $25K | Buy |
15
+5
| +50% | +$10.3K | ﹤0.01% | 3538 |
|
|
2021
Q2 | $29K | Buy |
10
+8
| +400% | +$39.5K | ﹤0.01% | 3542 |
|
|
2021
Q1 | $17K | Sell |
2
-5
| -71% | -$34.4K | ﹤0.01% | 4021 |
|
|
2020
Q4 | $49K | Buy |
7
+1
| +17% | +$5.24K | ﹤0.01% | 3152 |
|
|
2020
Q3 | $75K | Buy |
6
+2
| +50% | +$24.3K | ﹤0.01% | 3357 |
|
|
2020
Q2 | $52K | Buy |
+4
| New | +$45.1K | ﹤0.01% | 3017 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 2870 |
|
|
2019
Q2 | – | Hold |
0
| – | -$2K | – | 4419 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 3478 |
|
|
2018
Q3 | – | Sell |
-1
| Closed | -$2K | – | 4329 |
|
|
2018
Q2 | $2K | Buy |
+1
| New | +$4.64K | ﹤0.01% | 3394 |
|
|
2017
Q4 | – | Sell |
-7
| Closed | -$41K | – | 4118 |
|
|
2017
Q3 | $41K | Buy |
+7
| New | +$51.4K | ﹤0.01% | 2156 |
|
Tower Research Capital (TRC)'s ATXI Position: Q1 2025 in Review
Tower Research Capital (TRC) sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2025, closing a stake of 3,096 shares — an estimated $6.19K sold.
Tower Research Capital (TRC) first reported a position in ATXI in Q3 2017 and held it in 20 quarters. The position peaked at $75K in Q3 2020. 0 funds tracked by Wall St. Rank hold ATXI as of Q1 2025.
- Tower Research Capital (TRC) reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,096 Avenue Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $6.19K.
- Tower Research Capital (TRC) first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2017 and held it in 20 quarters.
- Tower Research Capital (TRC)'s Avenue Therapeutics, Inc. Common Stock position peaked at $75K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.